Stereotaxis Q1 2026 Earnings Call Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy STXS?
Source: seekingalpha
- Revenue Performance: In Q1 2026, Stereotaxis reported total revenue of $6.3 million, down from $7.5 million in the same quarter last year, with system revenue at $1.3 million and recurring revenue at $5 million, indicating pressure during the transition period.
- Product Approvals and Demand: The company received four FDA approvals in recent months for complex surgical robots and catheters, with demand for MAGiC significantly exceeding supply, and production expected to exceed 500 catheters per month by year-end to meet market needs.
- Future Outlook: Management reiterated guidance for double-digit revenue growth in 2026, expecting annual revenue to surpass $40 million, with Q3 and Q4 projected to exceed $10 million each, reflecting optimism for the latter half of the year.
- Financial Health: As of March 31, Stereotaxis had $14.6 million in cash and cash equivalents with no debt, and management expressed confidence in avoiding substantial dilution while pursuing non-dilutive financing opportunities to support future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STXS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STXS
Wall Street analysts forecast STXS stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.850
Low
4.00
Averages
4.20
High
5.00
Current: 1.850
Low
4.00
Averages
4.20
High
5.00
About STXS
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Stereotaxis to Announce Q1 Earnings on May 12
- Earnings Announcement Schedule: Stereotaxis is set to release its Q1 2023 earnings on May 12 after market close, with consensus EPS estimated at -$0.05 and revenue expected to reach $8.5 million, reflecting a 13.3% year-over-year growth.
- Performance Expectation Analysis: Over the past year, Stereotaxis has beaten EPS estimates 0% of the time and revenue estimates 25% of the time, indicating challenges in achieving profitability and meeting market expectations.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw one upward revision and no downward adjustments, while revenue estimates faced three downward revisions, suggesting a decline in market confidence regarding the company's future performance.
- Market Focus: Stereotaxis recently received FDA clearance for its Synchrony system and plans to acquire Robocath for $20 million, highlighting the company's strategic initiatives and expansion efforts in the medical robotics sector.
See More
Stereotaxis Q1 2026 Earnings Call Insights
- Revenue Performance: In Q1 2026, Stereotaxis reported total revenue of $6.3 million, down from $7.5 million in the same quarter last year, with system revenue at $1.3 million and recurring revenue at $5 million, indicating pressure during the transition period.
- Product Approvals and Demand: The company received four FDA approvals in recent months for complex surgical robots and catheters, with demand for MAGiC significantly exceeding supply, and production expected to exceed 500 catheters per month by year-end to meet market needs.
- Future Outlook: Management reiterated guidance for double-digit revenue growth in 2026, expecting annual revenue to surpass $40 million, with Q3 and Q4 projected to exceed $10 million each, reflecting optimism for the latter half of the year.
- Financial Health: As of March 31, Stereotaxis had $14.6 million in cash and cash equivalents with no debt, and management expressed confidence in avoiding substantial dilution while pursuing non-dilutive financing opportunities to support future growth.
See More
Stereotaxis Q1 Earnings Miss Expectations
- Disappointing Earnings: Stereotaxis reported a Q1 GAAP EPS of -$0.06, missing expectations by $0.01, with revenue of $6.2 million reflecting a 17.3% year-over-year decline and falling short of the anticipated $8.5 million, indicating ongoing challenges in revenue growth.
- Increased Operating Loss: The company experienced an operating loss of $6.0 million and a net loss of $5.9 million in Q1, slightly higher than last year's losses of $5.9 million and $5.8 million, highlighting persistent pressure on cost control and profitability.
- Adjusted Loss Figures: Adjusted operating and net losses were $2.9 million and $2.8 million respectively, compared to $2.7 million and $2.6 million in the previous year, indicating an increased burden from non-cash charges.
- Cash Flow and Liquidity: As of March 31, 2026, Stereotaxis had cash and cash equivalents of $14.6 million with no debt, although the negative free cash flow of $3.5 million suggests ongoing cash burn, yet the company maintains a relatively healthy liquidity position.
See More
Stereotaxis to Acquire Robocath for Up to $45 Million
- Acquisition Overview: US medical technology company Stereotaxis has agreed to acquire smart robotic solutions developer Robocath for up to $45 million, aiming to enhance its market position by expanding its platform to support a wider range of endovascular procedures.
- Revenue Projections: Robocath is expected to contribute approximately $2 million in annual revenue in the first post-acquisition year, with the transaction anticipated to break even in the third year, providing positive support for Stereotaxis's financial performance.
- Technology Integration: The deal will combine Stereotaxis's magnetic navigation technology with Robocath's mechanical robotic system, delivering a synergistic solution to enhance the efficiency of endovascular surgeries, while Stereotaxis plans to fast-track the development of Robocath's next-generation system, aiming for regulatory clearance in the US and Europe within two years.
- Strategic Significance: Stereotaxis Chairman and CEO David Fischel stated that acquiring Robocath represents a highly strategic addition, not only enhancing the company's technological leadership but also opening new avenues for growth and supporting the pursuit of other strategic opportunities.
See More
Stereotaxis Acquires Robocath to Enhance Surgical Robotics for Cardiology
- Acquisition Agreement: Stereotaxis has signed a definitive agreement to acquire French company Robocath for $20 million upfront, with potential contingent payments of up to $25 million based on regulatory and commercial milestones, reflecting the company's commitment to expanding its presence in the surgical robotics market.
- Technological Integration: The acquisition combines Stereotaxis' magnetic navigation system with Robocath's mechanical robotic platform, creating a fully integrated solution aimed at improving precision and efficiency in endovascular surgery, thereby reinforcing its market leadership.
- Revenue Expectations: Stereotaxis estimates that Robocath will contribute approximately $2 million in revenue in the first year post-acquisition, with breakeven expected by year three, supported by commercial synergies between the two companies.
- Market Performance Review: Stereotaxis shares have traded between $1.69 and $3.59 over the past year, closing at $2.03, up 5.73% from the previous day, indicating positive market sentiment towards its acquisition strategy.
See More
Stereotaxis to Acquire France's Robocath for $20M
- Acquisition Overview: Stereotaxis has agreed to acquire France-based Robocath for an upfront payment of $20 million, with additional contingent payments of up to $25 million tied to regulatory and commercial milestones, expected to close in mid-2026, significantly enhancing Stereotaxis' market position in endovascular procedures.
- Technological Integration: Robocath's flagship R-One+ system is currently the only commercially available robotic solution for percutaneous coronary interventions in Europe, and Stereotaxis plans to accelerate the development of Robocath's next-generation system and pursue regulatory submissions in the U.S. and Europe within the next two years, thereby expanding its product line.
- Financial Expectations: Robocath is estimated to contribute approximately $2 million in annual revenue during the first year post-acquisition, with expectations to break even by the third year post-acquisition, supported by commercial and operational synergies, further enhancing Stereotaxis' financial performance.
- Market Outlook: This acquisition not only strengthens Stereotaxis' technological capabilities but also lays the groundwork for future product innovation and manufacturing expansion, targeting over $40 million in annual revenue by 2026, demonstrating the company's strong confidence in the medical robotics market.
See More
Stereotaxis to Announce Q1 Earnings on May 12
- Earnings Announcement Schedule: Stereotaxis is set to release its Q1 2023 earnings on May 12 after market close, with consensus EPS estimated at -$0.05 and revenue expected to reach $8.5 million, reflecting a 13.3% year-over-year growth.
- Performance Expectation Analysis: Over the past year, Stereotaxis has beaten EPS estimates 0% of the time and revenue estimates 25% of the time, indicating challenges in achieving profitability and meeting market expectations.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw one upward revision and no downward adjustments, while revenue estimates faced three downward revisions, suggesting a decline in market confidence regarding the company's future performance.
- Market Focus: Stereotaxis recently received FDA clearance for its Synchrony system and plans to acquire Robocath for $20 million, highlighting the company's strategic initiatives and expansion efforts in the medical robotics sector.
See More
Stereotaxis Q1 2026 Earnings Call Insights
- Revenue Performance: In Q1 2026, Stereotaxis reported total revenue of $6.3 million, down from $7.5 million in the same quarter last year, with system revenue at $1.3 million and recurring revenue at $5 million, indicating pressure during the transition period.
- Product Approvals and Demand: The company received four FDA approvals in recent months for complex surgical robots and catheters, with demand for MAGiC significantly exceeding supply, and production expected to exceed 500 catheters per month by year-end to meet market needs.
- Future Outlook: Management reiterated guidance for double-digit revenue growth in 2026, expecting annual revenue to surpass $40 million, with Q3 and Q4 projected to exceed $10 million each, reflecting optimism for the latter half of the year.
- Financial Health: As of March 31, Stereotaxis had $14.6 million in cash and cash equivalents with no debt, and management expressed confidence in avoiding substantial dilution while pursuing non-dilutive financing opportunities to support future growth.
See More
Stereotaxis Q1 Earnings Miss Expectations
- Disappointing Earnings: Stereotaxis reported a Q1 GAAP EPS of -$0.06, missing expectations by $0.01, with revenue of $6.2 million reflecting a 17.3% year-over-year decline and falling short of the anticipated $8.5 million, indicating ongoing challenges in revenue growth.
- Increased Operating Loss: The company experienced an operating loss of $6.0 million and a net loss of $5.9 million in Q1, slightly higher than last year's losses of $5.9 million and $5.8 million, highlighting persistent pressure on cost control and profitability.
- Adjusted Loss Figures: Adjusted operating and net losses were $2.9 million and $2.8 million respectively, compared to $2.7 million and $2.6 million in the previous year, indicating an increased burden from non-cash charges.
- Cash Flow and Liquidity: As of March 31, 2026, Stereotaxis had cash and cash equivalents of $14.6 million with no debt, although the negative free cash flow of $3.5 million suggests ongoing cash burn, yet the company maintains a relatively healthy liquidity position.
See More
Stereotaxis to Acquire Robocath for Up to $45 Million
- Acquisition Overview: US medical technology company Stereotaxis has agreed to acquire smart robotic solutions developer Robocath for up to $45 million, aiming to enhance its market position by expanding its platform to support a wider range of endovascular procedures.
- Revenue Projections: Robocath is expected to contribute approximately $2 million in annual revenue in the first post-acquisition year, with the transaction anticipated to break even in the third year, providing positive support for Stereotaxis's financial performance.
- Technology Integration: The deal will combine Stereotaxis's magnetic navigation technology with Robocath's mechanical robotic system, delivering a synergistic solution to enhance the efficiency of endovascular surgeries, while Stereotaxis plans to fast-track the development of Robocath's next-generation system, aiming for regulatory clearance in the US and Europe within two years.
- Strategic Significance: Stereotaxis Chairman and CEO David Fischel stated that acquiring Robocath represents a highly strategic addition, not only enhancing the company's technological leadership but also opening new avenues for growth and supporting the pursuit of other strategic opportunities.
See More
Stereotaxis Acquires Robocath to Enhance Surgical Robotics for Cardiology
- Acquisition Agreement: Stereotaxis has signed a definitive agreement to acquire French company Robocath for $20 million upfront, with potential contingent payments of up to $25 million based on regulatory and commercial milestones, reflecting the company's commitment to expanding its presence in the surgical robotics market.
- Technological Integration: The acquisition combines Stereotaxis' magnetic navigation system with Robocath's mechanical robotic platform, creating a fully integrated solution aimed at improving precision and efficiency in endovascular surgery, thereby reinforcing its market leadership.
- Revenue Expectations: Stereotaxis estimates that Robocath will contribute approximately $2 million in revenue in the first year post-acquisition, with breakeven expected by year three, supported by commercial synergies between the two companies.
- Market Performance Review: Stereotaxis shares have traded between $1.69 and $3.59 over the past year, closing at $2.03, up 5.73% from the previous day, indicating positive market sentiment towards its acquisition strategy.
See More
Stereotaxis to Acquire France's Robocath for $20M
- Acquisition Overview: Stereotaxis has agreed to acquire France-based Robocath for an upfront payment of $20 million, with additional contingent payments of up to $25 million tied to regulatory and commercial milestones, expected to close in mid-2026, significantly enhancing Stereotaxis' market position in endovascular procedures.
- Technological Integration: Robocath's flagship R-One+ system is currently the only commercially available robotic solution for percutaneous coronary interventions in Europe, and Stereotaxis plans to accelerate the development of Robocath's next-generation system and pursue regulatory submissions in the U.S. and Europe within the next two years, thereby expanding its product line.
- Financial Expectations: Robocath is estimated to contribute approximately $2 million in annual revenue during the first year post-acquisition, with expectations to break even by the third year post-acquisition, supported by commercial and operational synergies, further enhancing Stereotaxis' financial performance.
- Market Outlook: This acquisition not only strengthens Stereotaxis' technological capabilities but also lays the groundwork for future product innovation and manufacturing expansion, targeting over $40 million in annual revenue by 2026, demonstrating the company's strong confidence in the medical robotics market.
See More
